Biblio

Found 20 results
[ Author(Asc)] Keyword Title Type Year
Filters: First Letter Of Last Name is H  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
H
P. Hoskins, Eisenhauer, E., Vergote, I. B., Dubuc-Lissoir, J., Fisher, B., Grimshaw, R., Oza, A. M., Plante, M., Stuart, G. C. E., and Vermorken, J. B., Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study., J Clin Oncol, vol. 18, no. 24, pp. 4038-44, 2000.
P. Hoskins, Vergote, I. B., Stuart, G. C. E., Cervantes, A., Tu, D., Carey, M. S., Provencher, D. M., Katsaros, D., P, G., and Eisenhauer, E., A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (OV.16). A GCIG Study., Proc.Am.Soc.Clin.Oncol. , vol. 26, no. 15S Part I, 2008.
T. Högberg, Signorelli, M., de Oliveira, C. F., Fossati, R., Lissoni, A., Sorbe, B., Andersson, H., Grenman, S., Lundgren, C., Rosenberg, P., Boman, K., Tholander, B., Scambia, G., Reed, N. Simon, Cormio, G., Tognon, G., Clarke, J., Sawicki, T., Zola, P., and Kristensen, G. B., Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies, Eur J Cancer, vol. 46, pp. 2422-31, 2010.
H. Hirte, Vergote, I. B., Jeffrey, J. R., Grimshaw, R. N., Coppieters, S., Schwartz, B., Tu, D., Sadura, A., Brundage, M., and Seymour, L., A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a NCIC Group Study., Gynecol Oncol, vol. 102, no. 2, pp. 300-8, 2006.
H. Hirte, Vergote, I. B., Jeffrey, J. R., Grimshaw, R. N., Coppieters, S., Schwartz, B., Tu, D., Sadura, A., Brundage, M., and Seymour, L., A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials G, Gynecol Oncol, vol. 102, pp. 300-8, 2006.
T. J. Herzog, Vermorken, J. B., Pujade-Lauraine, E., Provencher, D. M., Jagiello-Gruszfeld, A., Kong, B., Boman, K., Park, Y. Choi, Parekh, T., Lebedinsky, C., Gómez, J., and Monk, B. J., Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study., Gynecol Oncol, vol. 122, no. 2, pp. 350-5, 2011.
T. J. Herzog, Powell, M. A., Rader, J. S., Gibb, R. K., Lippmann, L., Coleman, R. L., and Mutch, D. G., Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer., Gynecol Oncol, vol. 111, no. 3, pp. 467-73, 2008.
M. L. Hensley, Barrette, B. A., Baumann, K. H., Gaffney, D. K., Hamilton, A. L., Kim, J. - W., Maenpaa, J. U., Pautier, P., Siddiqui, N. Ahmad, Westermann, A. M., and Ray-Coquard, I., Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S61-6, 2014.
F. Heitz, du Bois, A., Harter, P., Lubbe, D., Kurzeder, C., Vergote, I. B., Plante, M., and Pfisterer, J., Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG., Gynecol Oncol, vol. 129, no. 3, pp. 463-6, 2013.
K. Hasegawa, Nagao, S., Yasuda, M., Millan, D., Viswanathan, A., Glasspool, R. M., Devouassoux-Shisheboran, M., Covens, A., Lorusso, D., Kurzeder, C., Kim, J. - W., Gladieff, L., Bryce, J., Friedlander, M. Leonard, and Fujiwara, K., Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S90-5, 2014.
P. Harter, Gershenson, D., Lhomme, C., Lecuru, F., Ledermann, J. A., Provencher, D. M., Mezzanzanica, D., Quinn, M., Maenpaa, J. U., Kim, J. - W., Mahner, S., Hilpert, F., Baumann, K. H., Pfisterer, J., and du Bois, A., Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S5-8, 2014.
P. Harter, Sehouli, J., Reuss, A., Hasenburg, A., Scambia, G., Cibula, D., Mahner, S., Vergote, I. B., Reinthaller, A., Burges, A., Hanker, L., Pölcher, M., Kurzeder, C., Canzler, U., Petry, K. Ulrich, Obermair, A., Petru, E., Schmalfeldt, B., Lorusso, D., and du Bois, A., Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO., Int J Gynecol Cancer, vol. 21, no. 2, p. 295, 2011.
P. Harter, Johnson, T., Berton-Rigaud, D., Park, S. - Y., Friedlander, M. Leonard, Del Campo, J. M., Shimada, M., Forget, F., Mirza, M. R., Colombo, N., Zamagni, C., Chan, J. K., Imhof, M., Herzog, T. J., O'Donnell, D., Heitz, F., King, K., Stinnett, S., Barrett, C., Jobanputra, M., Xu, C. - F., and du Bois, A., BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study., Gynecol Oncol, vol. 140, no. 3, pp. 443-9, 2016.
M. L. Harrison, Hoskins, P., du Bois, A., Quinn, M., Rustin, G. J. S., Ledermann, J. A., Baron-Hay, S., and Friedlander, M. Leonard, Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study., Gynecol Oncol, vol. 100, no. 2, pp. 233-8, 2006.
M. L. Harrison, Hoskins, P., du Bois, A., Quinn, M., Rustin, G. J. S., Ledermann, J. A., Baron-Hay, S., and Friedlander, M. Leonard, Small cell of the ovary, hypercalcemic type – analysis of combined experience and recommendation for management. A GCIG study, Gynecol Oncol, vol. 100, pp. 233-8, 2006.
P. Harper, ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date., Semin Oncol, vol. 24, no. 5 Suppl 15, pp. S15-23-S15-25, 1997.
K. Harano, Hirakawa, A., Yunokawa, M., Nakamura, T., Satoh, T., Nishikawa, T., Aoki, D., Ito, K., Ito, K., Nakanishi, T., Susumu, N., Takehara, K., Watanabe, Y., Watari, H., and Saito, T., Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group., Int J Clin Oncol, vol. 21, no. 1, pp. 168-76, 2016.
K. Harano, Terauchi, F., Katsumata, N., Takahashi, F., Yasuda, M., Takakura, S., Takano, M., Yamamoto, Y., and Sugiyama, T., Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: JGOG Trial (JGOG3016)., Ann Oncol, vol. 25, no. 1, pp. 251-7, 2014.
L. C. Hanker, Loibl, S., Burchardi, N., Pfisterer, J., Meier, W., Pujade-Lauraine, E., Ray-Coquard, I., Sehouli, J., Harter, P., du Bois, A., ,, and Group, G. I. N. E. C. O. Study, The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy, Ann Oncol, vol. 23, pp. 2605-12, 2012.
D. Handolias, Quinn, M., Foo, S., Mileshkin, L. R., Grant, P., Dutu, G., and Rischin, D., Oral cyclophosphamide in recurrent ovarian cancer, Asia Pac J Clin Oncol, 2013.